SLEEKSCAPE'S 2022 CANNABIS & MARIJUANA MANIA GRAND SALAMI -- PART II

[sleekscape]

Amy Abernethy’s Twitter = FDA is playing ball

We just saw the news about Lowell Schiller being a keynote speaker at a National Hemp Business Summit on 8/13/19

His partner in crime in the CBD Working Group is Amy Abernethy

Here is Ms. Abernethy’s tweet today:

3/3 Over 100 speakers presented at the May 31st public hearing. There are 3417 comments on the public docket with 4 days to go. Please submit comments & data by 7/16/19. We plan to report on our progress around end of summer/early fall. https://t.co/EK3FxsPq0F

— Dr. Amy Abernethy (@DrAbernethyFDA) July 12, 2019

FDA is expediting its work to address the many questions about cannabidiol (CBD). This is an important national issue with public health impact, & an important topic for American hemp farmers and many other stakeholders.

We are enthusiastic about research into the therapeutic benefits of CBD products but also need to balance safety. To understand the breadth of issues and gather data on safety we have conducted a public hearing, reviewed the medical literature, and have an open public docket.

Over 100 speakers presented at the May 31st public hearing. There are 3417 comments on the public docket with 4 days to go. Please submit comments & data by 7/16/19. We plan to report on our progress around end of summer/early fall.

— — —

I think the code word for “balance safety” is going to be THC-Free

The possibility of elevated liver enzymes at high doses is already well-known and nothing a warning label on CBD products couldn’t address

I believe THC is going to wind up being where the FDA draws a red line, at least in terms of what they will permit to cross state lines — I don’t foresee any crackdown on THC-containing CBD products per se, just that THC-Free CBD products will be the first ones to gain permission to be sold nationally


Sleek